- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
H Lundbeck B (HLUNb)
Track today's live H Lundbeck B (HLUNb) share price, performance and key data on this page with our current Copenhagen:HLUNb stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the H Lundbeck B share price on the Copenhagen exchange. Use the dropdown to switch exchange for the HLUNb share price, head to our technical summary section, which provides analysis on H Lundbeck B share price buy/sell indicators using real-time data (or discuss the H Lundbeck B (HLUNb) stock price today with other investors in the H Lundbeck B CSE share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current CSE:HLUNb share price (ISIN: DK0061804770) to enhance your trading decisions with our free investment tools and resources.
What Is the H Lundbeck B Share Price Today?
The H Lundbeck B share price today is 43.14.
What Is the Stock Symbol for H Lundbeck B
The stock symbol (or 'ticker') for H Lundbeck B is "HLUNb."
What Stock Exchange Does H Lundbeck B Trade On?
H Lundbeck B is listed and trades on the Copenhagen stock exchange.
Is H Lundbeck B a Good Stock to Buy?
Determining whether H Lundbeck B (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current CSE:HLUNb share price (ISIN: DK0061804770) to enhance your trading decisions with our free investment tools and resources.
What Is the H Lundbeck B Share Price Today?
The H Lundbeck B share price today is 43.14.
What Is the Stock Symbol for H Lundbeck B
The stock symbol (or 'ticker') for H Lundbeck B is "HLUNb."
What Stock Exchange Does H Lundbeck B Trade On?
H Lundbeck B is listed and trades on the Copenhagen stock exchange.
Is H Lundbeck B a Good Stock to Buy?
Determining whether H Lundbeck B (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
43.14
+0.62(+1.46%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
42.16
43.18
52 wk Range
35.30
47.78
Earnings results expected tomorrow
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
42.1643.18
52 wk Range
35.3047.78
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.67%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.67%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
HLUNb Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
48.13
Upside
+11.56%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 4 consecutive years
H Lundbeck B receives Investment Bank Analyst Rating Update- Investing.com
Pro
H Lundbeck B receives Investment Bank Analyst Rating Update- Investing.com
Pro
- H Lundbeck B receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
4 Buy
7 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 48.13
(+11.56% Upside)
Earnings
Latest Release
11/05/2026
EPS / Forecast
1.67 / 1.43
Revenue / Forecast
7.13B / 6.61B
Compare HLUNb to Peers and Sector
Metrics to compare | HLUNb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHLUNbPeersSector | |
|---|---|---|---|---|
P/E Ratio | 11.0x | 16.3x | −0.3x | |
PEG Ratio | 0.76 | 0.03 | 0.00 | |
Price/Book | 1.6x | 2.5x | 2.6x | |
Price / LTM Sales | 1.6x | 2.9x | 3.1x | |
Upside (Analyst Target) | 6.5% | 12.9% | 49.0% | |
Fair Value Upside | Unlock | 11.5% | 6.3% | Unlock |
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the H Lundbeck B (Copenhagen: HLUNb) Share Price Today?
The H Lundbeck B stock price today is 43.14 DKK.
What Stock Exchange Does H Lundbeck B (HLUNb) Trade On?
H Lundbeck B is listed and trades on the Copenhagen Stock Exchange.
What Is the Ticker (Stock Symbol) for H Lundbeck B?
The stock symbol (also called a 'ticker') for H Lundbeck B is "HLUNb."
Does H Lundbeck B Pay Dividends? What’s The Current HLUNb Dividend Yield?
Yes, HLUNb Pays Dividends to its Shareholders. The current H Lundbeck B dividend yield is 2.67%.
What Is the Current H Lundbeck B Market Capitalisation?
As of today, H Lundbeck B (Copenhagen: HLUNb) market cap is 41.42B DKK.
What Is H Lundbeck B's (HLUNb) Earnings Per Share (TTM)?
The H Lundbeck B EPS is currently 3.76 (Trailing Twelve Months).
When Is the Next H Lundbeck B Earnings Date?
H Lundbeck B's next earnings report will be released on 19/08/2026.
Is HLUNb a Buy or Sell From a Technical Analyst Perspective?
Based on today's H Lundbeck B moving averages and other technical indicators, the daily buy/sell signal for HLUNb stock is Strong Buy.
How Many Times Has H Lundbeck B Stock Split?
H Lundbeck B has split 0 times. (See the HLUNb stock split history page for full effective split date and price information.)
How Many Employees Does H Lundbeck B Have?
H Lundbeck B has 5000 employees, based on their latest Companies House report.
What is the current trading status of H Lundbeck B (Copenhagen: HLUNb)?
As of 18/08/2026, H Lundbeck B (HLUNb) is trading at a share price of 43.14 DKK, with a previous close of 43.14 DKK. The stock has fluctuated within a day range of 42.16 DKK to 43.18 DKK, while its 52-week range spans from 35.30 DKK to 47.78 DKK.
What Is H Lundbeck B (HLUNb) Price Target According to Analysts?
The average 12-month price target for H Lundbeck B is 48.13 DKK, with a high estimate of 65 DKK and a low estimate of 34 DKK. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +11.56% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.